PHINMA University of Pangasinan

College of Health Sciences

Name of Student Nurse: _________________________________________ Date: _____________________

Level/block/group: _______________ Hospital/Area: ____________________________ Clinical Instructor:_______________

NAME OF DRUG MECHANISM OF ACTION CONTRAINDICATIONS SIDE EFFECTS ADVERSE EFFECTS NURSING RESPONSIBILITIES
GENERIC NAME Contraindicated in Common side effects of CNS: Headache, dizziness, Before:
Omeprazole is a gastric antisecretory clients with the ff. Omeprazole includes: asthenia, vertigo, -Assess other medications patients
agent and is also known as PPI. It blocks conditions:  Headache insomnia, apathy, anxiety, may be taking for effectiveness and
Omeprazole the final step in gastric acid secretion by  Hypersensitivity  Nausea paresthesias, dream interactions especially those
specific inhibition of hydrogen- to omeprazole  Vomiting abnormalities dependent on acid environment for
BRAND NAME potassium ATPase enzyme present on or its  Diarrhea absorption.
the secretory surface of the gastric components  Abdominal pain Dermatologic: Rash,
Losec, Prilosec, Zegerid, parietal cell.  Use cautiously  Gas (Flatulence) Inflammation, urticarial, -Assess for hypersensitivity to the drug
Losecosan, omecat with pregnancy,  Constipation, pruritus, alopecia, dry skin and allergies
Specifically, omeprazole is used on lactation  Fever
CLASSIFICATION patients who have had an ileostomy to  Cold symptoms GI: Diarrhea, abdominal -Administer before meals
help control excess stomach acid by (stuffy pain, nausea, vomiting,
inhibiting gastric acid secretion for up to nose, sneezing, constipation, dry mouth, -Advised patient to swallow capsules
Antisecretory drug, 36 hours 11, which also reduces the tongue atrophy whole- not to open, chew or crush
and sore throat)
Antacids, Antireflux stoma output to minimizes fluid and them.
Agents & Antiulcerants electrolyte loss. Respiratory: URI
symptoms, cough,
epistasis During:
-If administering oral suspension,
INDICATION
Other: Cancer in empty the packet into a small cup
preclinical studies, back containing water. Stir and have the
-Erosive esophagitis and pain, fever patient drink immediately. DO not use
accompanying any other diluent
symptoms caused by
GERD such as heartburn -Assess GI system: bowel sounds every
and gastric acid hyper 8 hours, abdomen for pain and
secretion. swelling, appetite loss.

-H.pylori infection and -Caution patient to avoid alcohol,

duodenal ulcer disease, salicylates, ibuprofen as they may
to eradicate H.pylori cause GI irritation
 -In case a patient experiences
DOSAGE & FREQUENCY anorexia, encourage small frequent
Adult: meals to maintain adequate nutrition.
Packet
 2.5mg After:
 10mg -Monitor the effectiveness and
Suspension adverse reactions of the medication
 2mg/mL
Tablet, delayed release -Encourage patient to have regular
 20mg (Prilosec medical follow-up visits
OTC,
OmepraCare) -Consider the diagnosis for patients
Capsule, delayed taking this drug who have diarrhea
release that does not improve.
 10mg (generic)
 20mg -Report severe or unresolved adverse
(OmepraCare DR, effects and changes in respiratory
generic) status. Inform physician if patient
 40mg (generic) tends to become pregnant as
Oral disintegrating breastfeeding is not recommended.
tablets
 20mg -Educate the client regarding the
appropriate use of medication,
Duodenal Ulcer interventions to reduce side effects,
and adverse symptoms to report
 20 mg PO qDay
for 4-8 weeks
 Safety and
efficacy of
omeprazole for
maintenance
treatment past
1 year not
established
Helicobacter Pylori
Infection
 Various
regimens exist
of PPIs
 combined with
antibiotics, an
example is
listed below
 20 mg PO q12hr
for 10 days,
WITH
 Amoxicillin
1000 mg PO
q12hr, AND
 Clarithromycin
500 mg PO
q12hr for 10-14
days
Dosing considerations
 This regimen is
available as a
prepackaged 10-
day supply of
omeprazole,
amoxicillin, and
clarithromycin
from Dava
Pharms Inc, for
eradication of H
pylori
Gastric Ulcer
 40 mg PO qDay
for 4-8 weeks
GERD
 20 mg PO qDay
for 4 weeks
Erosive Esophagitis
 20 mg PO qDay
for 4-8 weeks
 Maintenance:
 20 mg PO qDay
for up to 1 year
Hypersecretory
Conditions (eg,
Zollinger-Ellison
Syndrome)
 60 mg PO qDay
(initial) up to
360 mg/day
divided q8hr PO
 If dose >80 mg,
divide it
Dosage Modifications
Hepatic impairment:
Not studied; expert
analysis recommends a
reduction in dose,
especially for
maintenance of healing
of erosive esophagitis
Renal impairment:
Dose adjustments not
necessary

Pediatric:
Packet
 2.5mg
 10mg
Suspension
 2 mg/mL
Tablet/capsule
 10mg (generic)
 20mg
(OmepraCare DR,
generic)
 40mg (generic)
Oral disintegrating
tablets
 20mg
GERD
Indicated for treatment
of GERD:
 <1 year: Safety
and efficacy not
established
 5-10 kg: 5 mg
PO qDay
 10-20 kg: 10 mg
PO qDay
 >20 kg: 20 mg
PO qDay
Erosive Esophagitis
Indicated for treatment
and to maintain healing
of erosive esophagitis
caused by acid-
mediated GERD
Treatment
 <1 month:
Safety and
efficacy not
established
 Aged 1 month
to <1 year
o 3 to <5
kg: 2.5 mg
qDay
o 5 to <10
kg: 5 mg
qDay
o ≥10 kg:
10 mg qDay
o May
treat for up
 to 6 weeks
 Aged 1-16 years
o 5 to <10
kg: 5 mg PO
qDay
o 10 to
<20 kg: 10
mg PO qDay
o ≥20 kg:
20 mg PO
qDay
o May
treat for 4-8
weeks
Maintenance of healing
 <1 year: Safety
and efficacy not
established
 ≥1 year:
Controlled trials
for maintenance
do not extend
beyond 12
months
Neonates (Off-label)

 Refractory
duodenal ulcer
or reflux
esophagitis: 0.5-
1.5 mg/kg PO
qDay for up to 8
weeks